Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM NASDAQ:ALZN NASDAQ:ATXI NASDAQ:PMCB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$2.45-3.7%$5.89$2.33▼$37.80$6.63M0.8865,962 shs57,587 shsALZNAlzamend Neuro$2.44+0.4%$2.73$2.06▼$24.93$7.04M-0.3284,289 shs73,380 shsATXIAvenue Therapeutics$0.57+1.2%$0.42$0.17▼$3.54$1.81MN/A169,969 shs967 shsPMCBNuvilex$0.94-2.2%$1.01$0.80▼$2.42$6.52M-0.29115,734 shs32,937 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech-3.66%-9.37%-19.77%-73.23%-93.11%ALZNAlzamend Neuro+0.41%-2.01%-3.17%-39.45%-88.56%ATXIAvenue Therapeutics+1.24%-1.72%+25.27%+161.59%-77.47%PMCBNuvilex-2.19%-3.20%-7.03%-11.83%-38.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.0871 of 5 stars3.50.00.00.01.10.00.0ALZNAlzamend Neuro2.6751 of 5 stars3.52.00.00.01.83.30.6ATXIAvenue Therapeutics2.1869 of 5 stars0.03.00.04.62.30.01.9PMCBNuvilex1.9456 of 5 stars0.03.00.00.03.80.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.0011,138.25% UpsideALZNAlzamend Neuro 3.00Buy$45.001,744.26% UpsideATXIAvenue Therapeutics 0.00N/AN/AN/APMCBNuvilex 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATXI, ALZN, AIM, and PMCB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025ALZNAlzamend NeuroAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$180.00 ➝ $45.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$121K54.78N/AN/A$0.20 per share12.24ALZNAlzamend NeuroN/AN/AN/AN/A$4.95 per shareN/AATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/APMCBNuvilexN/AN/AN/AN/A$7.56 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.68N/AN/AN/A-12,594.21%-421.73%-147.54%N/AALZNAlzamend Neuro-$4.51MN/A0.00N/AN/AN/A-181.34%-116.84%9/10/2025 (Estimated)ATXIAvenue Therapeutics-$10.38M-$0.950.03∞N/AN/A-471.57%-296.50%11/12/2025 (Estimated)PMCBNuvilex$30.66M$2.590.36∞N/AN/A4.60%3.76%9/15/2025 (Estimated)Latest ATXI, ALZN, AIM, and PMCB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/10/2025N/AALZNAlzamend Neuro-$3.69N/AN/AN/AN/AN/A8/8/2025Q4 2025PMCBNuvilexN/A-$0.25N/A-$2.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/AALZNAlzamend NeuroN/AN/AN/AN/AN/AATXIAvenue TherapeuticsN/AN/AN/AN/AN/APMCBNuvilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75ALZNAlzamend NeuroN/A6.586.58ATXIAvenue TherapeuticsN/A2.702.70PMCBNuvilexN/A7.687.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%ALZNAlzamend Neuro49.61%ATXIAvenue Therapeutics17.34%PMCBNuvilex34.24%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%ALZNAlzamend Neuro30.21%ATXIAvenue Therapeutics1.80%PMCBNuvilex10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech202.71 million68.74 millionNot OptionableALZNAlzamend Neuro42.90 million2.02 millionNo DataATXIAvenue Therapeutics43.18 million2.02 millionNot OptionablePMCBNuvilex46.80 million6.10 millionOptionableATXI, ALZN, AIM, and PMCB HeadlinesRecent News About These CompaniesPharmaCyte Biotech, Inc. Announces Closing of $7 Million FinancingAugust 20, 2025 | businesswire.comPharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing InvestorsAugust 18, 2025 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 18, 2023 | msn.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 15, 2023 | finance.yahoo.comPharmaCyte Biotech Inc PMCBDecember 5, 2023 | morningstar.comMWith biotech in a slump, the industry’s job market is upside downNovember 28, 2023 | statnews.comSThe return of biotech’s “bump factor” amid an economic downturnNovember 24, 2023 | statnews.comSPharmaCyte Biotech: Entry Into A Material Definitive Agreement, Other Events, Financial Statements And ExhibitsNovember 18, 2023 | cbonds.comCPharmaCyte Biotech Invests In Femasys - Quick FactsNovember 15, 2023 | markets.businessinsider.comFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechNovember 15, 2023 | finance.yahoo.comBiotech power broker John Maraganore offers advice to the next crop of entrepreneursOctober 23, 2023 | statnews.comSPharmaCyte completes tender offer to purchase sharesJune 15, 2023 | msn.comPharmaCyte Biotech Announces Final Results of Tender OfferJune 15, 2023 | finance.yahoo.comLos Angeles Biotech NewsJune 14, 2023 | bizjournals.comPharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per ShareMay 11, 2023 | finance.yahoo.comBiotech ETFs’ Performance Deserves A LookApril 21, 2023 | nasdaq.com300 biotech and pharma CEOs including the head of Pfizer call for a reversal of the abortion pill banApril 12, 2023 | fortune.comHow DFW Becomes a Biotech HubApril 9, 2023 | dmagazine.comDNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?By Jordan Chussler | August 14, 2025Alphabet Reclaims $200 Threshold—Bull Run Reignited?By Ryan Hasson | August 12, 2025AI Glasses to Replace Smartphones? Meta Is Taking Aim at AppleBy Leo Miller | August 16, 2025Is It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025ATXI, ALZN, AIM, and PMCB Company DescriptionsAIM ImmunoTech NYSE:AIM$2.45 -0.09 (-3.66%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$2.50 +0.06 (+2.37%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Alzamend Neuro NASDAQ:ALZN$2.44 +0.01 (+0.41%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$2.44 0.00 (-0.16%) As of 08/29/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Avenue Therapeutics NASDAQ:ATXI$0.57 +0.01 (+1.24%) As of 08/29/2025 09:48 AM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Nuvilex NASDAQ:PMCB$0.94 -0.02 (-2.19%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.93 -0.01 (-1.38%) As of 08/29/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
